Adamis Pharma announced license to commercialize Tempol, a novel investigational anti-inflammatory and antioxidant drug for treatment of respiratory diseases
| |

Adamis Pharma announced license to commercialize Tempol, a novel investigational anti-inflammatory and antioxidant drug for treatment of respiratory diseases

On Jun. 15, 2020, Adamis Pharma announced a license to commercialize Tempol, a novel patented investigational drug for…